In addition to these prospective data, retrospective studies have also failed to demonstrate a benefit of metformin in GnRH antagonist cycles, making its routine use for the prevention of OHSS unjustified in this context. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.